Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
NCT06401330Phase 3Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Apr 2025
- Primary completion
- Feb 2031
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Targeted Liposomes
- Countries
- 4
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, carboplatin in Wilms' tumor, sponsored by Children's Oncology Group. Started Apr 2025; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabcarboplatin
03
Conditions
Wilms' tumor
Beyond the preview
Go deeper on NCT06401330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06401330.